Echo IQ trial shows EchoSolv screening platform improves diagnosis of severe aortic stenosis
A flagship clinical trial of Echo IQ’s (ASX: EIQ) EchoSolv artifical intelligence (AI) medical software technology has identified 72% more patients with severe aortic stenosis than human diagnosis alone.